Viewing StudyNCT00101985



Ignite Creation Date: 2024-05-05 @ 11:41 AM
Last Modification Date: 2024-10-26 @ 9:11 AM
Study NCT ID: NCT00101985
Status: COMPLETED
Last Update Posted: 2015-04-13
First Post: 2005-01-18

Brief Title: Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome IBS
Sponsor:
Organization: GlaxoSmithKline

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 741
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE2
Observational Models:
Time Perspective List:
Who Masked List: